IP Library Granted Patent US 8,889,140
Granted Patent B2
US 8,889,140 · App. 12/601,522 · Granted Nov 18, 2014

Compositions and methods for tissue repair

Inventors: Randall J. Lee (Hillsborough, CA); Shirley Mihardja (Daly City, CA); Manley Huang (Palo Alto, CA); James W. Larrick (Mountain View, CA)
Assignees: TransTarget, Inc.; The Regents of the University of California
C07K14/78C07K14/7151C07K14/70525C07K14/70542A61K47/48415A61K47/48538C12N9/6475C07K2319/00C07K14/4721C07K14/52C07K14/70553C07K14/70564C07K14/4716C07K16/2833
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,140
App. No.
12/601,522
Granted
Nov 18, 2014
Kind
B2
Abstract

The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.

Claims (8)

1. A composition for repair of an injured tissue, the composition comprising

an injury-associated antigen-specific binding component conjugated to an extracellular matrix derived (EMD) peptide,

wherein the injury-associated antigen-specific binding component is an antibody that specifically binds myosin heavy chain and

wherein the EMD peptide comprises a Hep III peptide comprising the sequence of SEQ ID NO:2, and exhibits the ability to: (i) activate cells; (ii) attach cells; and (iii) exhibits a chemotropic property.

2. The composition of claim 1 , wherein the EMD peptide further exhibits an angiogenic property.

3. The composition of claim 1 , wherein the injury-associated antigen-specific binding component and the EMD peptide are chemically or recombinantly conjugated.

4. The composition of claim 1 , wherein the antibody is selected from the group consisting of a (Fab)′2 fragment, an ScFv, a human antibody, and a humanized antibody.

5. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: HUANG, MANLEY; LARRICK, JAMES W.
To: TRANSTARGET, INC.
Reel/Frame 024432/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: LEE, RANDALL J.; MIHARDJA, SHIRLEY
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024432/0523 →
Continuity (2)
Provisional Application 60941051 · May 31, 2007
Related Publication 20100291080A1 · Nov 18, 2010